Explore evidence

1,462 parasites/μLLa parasitémie moyenne de P. malariae calculée était de 1462 parasites par μL de sang avec un écart type de 1051 parasites par μL.

MalipaludismeHAL · Unilimdocument of 214 observations

94.7 %Chez les 95 patients du groupe Kollé, 90 présentaient des formes asexuées de Plasmodium falciparum, soit 94,7 %.

MalipaludismeHAL · Unilimdocument of 62 observations

87.5 %Chloroquine has 85–90% efficacy for treating uncomplicated malaria in Mali.

Malipaludismepublished 2002The American journal of tropical medicine and hygieneeurope_pmcdocument of 4 observationsDOI 10.4269/ajtmh.2002.67.604

30 msUn patient porteur des variantes rs2116964399 et NM_000238.4:c.1604T > A a présenté une prolongation de l'intervalle QTc de 30 ms après 2 jours de traitement par DHA-PQ.

Maliprolongation de l'intervalle QTcHAL · Unilimdocument of 62 observations

53 childrenOf the 560 missed opportunities of hospital referral, 53 (9.5%) were from Mali.

Malipneumonie sévèreobserved 14 June 2021 to 20 June 2022HAL · Unilimdocument of 187 observations

100,000 parasitized_red_blood_cells_per_microliterThe two correlates of disease were parasitemia above 100,000 parasitized red blood cells per microliter and a low baseline hemoglobin level.

Malipaludismepublished 2004Bloodeurope_pmcdocument of 2 observationsDOI 10.1182/blood-2003-11-3884

30.9 %The lowest seasonal malaria chemoprevention (SMC) coverage rate (30.9%) was observed in the health district of Inekar (Menaka region in the north) in the year 2017–2018.

Malipaludismeobserved 2017–2018HAL · Unilimdocument of 111 observations

75 %Coinfection with Mansonella perstans was common, occurring in 75% (30 of 40) of a subset of individuals.

Maliloasepublished 2003American Journal of Tropical Medicine and HygieneOpenAlexdocument of 3 observations

41.8 msLes porteurs de la variante génétique rs1805121 ont présenté une prolongation QTc de 41,8 ms après exposition à la pipéraquine, contre 14,4 ms chez les témoins.

MalipaludismeHAL · Unilimdocument of 62 observations

3,000,000,000 treatment_coursesAlmost three billion treatment courses for malaria were supplied over the period 2010–2017.

Malipaludismeobserved 2010-2017published 2019Parasite (Paris, France)europe_pmcdocument of 2 observationsDOI 10.1051/parasite/2019016

73 %LLIN utilization in the general population in Mali was 73% at the national level according to the 2018 DHS.

Malipaludismeobserved 2018HAL · Unilimdocument of 111 observations

72 heuresP. malariae a un cycle intra-érythrocytaire long de 72 heures.

MalipaludismeHAL · Unilimdocument of 214 observations

6.7 %A significant cross-reactive antibody response to RBD was detected in pre-COVID-19 and malaria samples at 6.7%.

MalipaludismeHAL · Unilimdocument of 67 observations

95.22 %The diagnostic performance of HemotypeSC® for possible sickle cell disease (SCD) in Mali from April to August 2021 showed a sensitivity of 95.22% [95% CI: 93.74–96.70].

Malipossible sickle cell disease (SCD)observed April–August 2021HAL · Unilimdocument of 103 observations

6.38 USDIn Mali, the cost per child of seasonal malaria chemoprevention was $6.38 for four cycles between 2015 and 2016.

Malipaludismeobserved 2015–2016HAL · Unilimdocument of 110 observations

78.33 %HemotypeSC® had a sensitivity of 78.33% (95% CI: 67.91–88.76) to detect sickle cell disease.

MalidrépanocytoseHAL · Unilimdocument of 103 observations

25 per_100000Entre 2000 et 2019, le nombre de décès associés au paludisme est passé de 25 à 10 pour 100 000 personnes exposées au risque.

Malipaludismeobserved 2000 à 2019HAL · Unilimdocument of 214 observations

0 p-valueIn Mali, a retrospective study conducted at CHU Gabriel Touré in Bamako between 2014 and 2018 reported a significant drop in case fatality (p = 0.0001) for cerebral malaria after SMC introduction.

Malipaludismeobserved 2014–2018HAL · Unilimdocument of 147 observations

Elevated severity in inhabitants over 15 years was observed during the malaria outbreak in the Kidal region.

MalipaludismeHAL · Unilimdocument of 80 observations

Recessive homozygotes for CD36 (rs321198) had significantly lower anti-malarial antibody levels to MSP2.

MaliMSP2 · paludismepublished 2015Malaria journaleurope_pmcdocument of 3 observations

57.33 %Mastomys erythroleucus was the most dominant species (57.33%, 43/75) in the Faladjè settlement.

Malibacteria, parasites and pathogenic viruses · epidemic diseaseobserved December 2016published 2023Variation in Relative Abundance of Small Mammal species Caught in Two Different Ecosystemseurope_pmcdocument of 3 observationsDOI 10.20944/preprints202304.0285.v1

0.412 per_1000_person_weeksMalaria incidence in the Kidal region was 0.412 cases per 1,000 person-weeks in 2021.

Malipaludismeobserved 2021HAL · Unilimdocument of 80 observations

17.4 %The malaria vaccine FMP2.1/AS02(A) had an efficacy of 17.4% against the primary end point of clinical malaria in Malian children.

Malipaludismepublished 2011The New England journal of medicineeurope_pmcdocument of 5 observationsDOI 10.1056/nejmoa1008115

6 foldAnti-AMA-1 antibodies increased significantly in both malaria vaccine groups, peaking at more than 6-fold higher than baseline in the full-dose group.

Malipaludismepublished 2008PloS oneeurope_pmcdocument of 2 observations

Almost half of the mothers interviewed stated that their child had had soumaya during the past rainy season.

Malisoumayaobserved past rainy seasonpublished 2000Tropical medicine & international health : TM & IHeurope_pmcdocument of 5 observations